Abstract
Alois Alzheimer (1864–1915) combined the clinical and pathological approach to brain disease, and made the study of dementia his special sphere. In the course of these studies in 1907 he published the report ‘On a Peculiar Disease of the Cerebral Cortex’ (Uber eine eigenartige Erkrankung de Hirnrinde) (see Wilkins and Brody, 1969). This ‘peculiar disease’ was soon to be designated Alzheimer’s disease (AD) by Alois’s head of department, Kraepelin. The original report described a 56-year-old woman who had died following a five- to six-year illness characterized by disorientation, memory loss and personality changes. Post-mortem microscopic examination of cortical brain tissue revealed a high density of lesions currently described as senile plaques and neurofibrillary tangles, along with loss of pyramidal neurones.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Allen S.J. (1984) Neurochemical changes in normal ageing and Alzheimer’s disease, University of London, PhD Thesis.
Anderson K.J., Bridges, R.J. and Cotman, C.W. (1991) Increased density of excitatory amino acid transport sites in the hippocampal formation following an entorhinal lesion. Brain Res., 562, 285–290.
Andrade, R. and Nicoll, R.A. (1987) Novel anxiolytics discriminate between postsynaptic and presynaptic mediating different physiological responses on single neurones of the rat hippocampus. Naunyn-Schmiedeberg’s Arch. Pharmacol. Exp. Pathol,. 336, 5–10.
Araneda, R. and Andrade, R. (1991) 5-Hydroxytryptamine2 and 5-hydroxytryptamine1A receptors mediate opposing responses on membrane excitability in rat association cortex. Neuroscience, 40, 399–412.
Ball, M.J. (1978) Topographic distribution of neurofibrillary tangles and granulovacuolar degeneration in hippocampal cortex of aging and demented patients. A quantitive study. Acta Neuropathol, 42, 73–80.
Beal, M.F., Mazurek, M.H., Chattha, G.K. et al. (1986) Neuropeptide Y immunoreactivity is reduced in cerebral cortex in Alzheimer’s disease. Ann. Neurol., 20, 282–288.
Beal, M.F., Clevens, R.A., Chattha, G.K. et al. (1988) Galanin-like immunoreactivity is unchanged in Alzheimer’s disease and Parkinson’s disease. J. Neurochem., 51, 1935–1941.
Becker, R.E. (1991) Therapy of the cognitive deficit in Alzheimer’s disease, in Cholinergic basis for Alzheimer’s therapy, (eds R.E. Beck and E. Giacobini) Birkhauser, Boston, pp. 1–22.
Birnbaumer, L. (1990) G Proteins in signal transduction. Anna. Rev. Pharmacol. Toxico., 30, 675–705.
Bjork, L., Cornfield, L.J., Nelson, D.L. et al. (1991) Pharmacology of the novel 5-hydroxytryptamine 1A receptor antagonist (S)-5-fluoro-8-hydroxy-2-(dipropylamino) tetralin: inhibition of (R)-8-hydroxy 2-(dipropylamino)tetralin-induced effects./. Pharmacol. Exp. Ther., 258, 58–65.
Bowen, D.M., (1990) Treatment of Alzheimer’s disease: molecular pathology versus neurotransmitter-based therapy. Br. J. Psychiatry, 157, 327–330.
Bowen, D.M., Francis, P.T., Pangalos, M.N. et al. (1992) Treatment strategies for Alzheimer’s disease. Lancet, 339, 132–133.
Bowen, D.M., White, P., Spillane, J.A. et al. (1979) Accelerated ageing or selective neuronal loss as an important cause of dementia. Lancet, 1, 11–14.
Bowen, D.M., Allen, S.J., Benton, J.S. et al. (1983) Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer’s disease. J. Neurochem., 41, 266–272.
Bowen, D.M., Beyreuther, K., Cross, A. J. et al. (1988) Cell injury: Molecular biology and genetic basis, in Etiology of Dementia of the Alzheimers Lype, (eds A.S. Henderson and J.H. Henderson), Wiley, Chichester, pp. 165–176.
Bowen, D.M., Najlerahim, A., Procter, A.W. et al. (1989) Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life. Proc. Natl. Acad. Sci. USA, 86, 9504–9508.
Braak, H. and Braak, E. (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol., 82, 239–259.
Chalmers, D.T., Dewar, D., Graham, D.I. et al. (1990) Differential alterations of cortical glutamatergic binding sites in senile dementia of the Alzheimer type. Proc. Natl. Acad. Sci. USA, 87, 1325–1356.
Chawluk, J.B., Alavi, A., Dann, R., Zimmerman, R.A. and Reivich, M.J. (1987) Positron emission tomography in aging and dementias; effect of cerebral atrophy. J. Nucl. Med., 28, 431–437.
Christensen, I.T., Reinhardt, A., Nielsen, B. et al. (1989) Excitatory amino acid agonists and partial agonists. Drug Design and Delivery, 5, 57–71.
Christie, J.E., Shering, A., Ferguson, J. and Glen, A.I.M. (1981) Physostigmine and arecoline; effects of intravenous infusions in Alzheimer’s presenile dementia. Br. J. Psychiatry, 138, 46–50.
Chu, C.M., Penney, J.B. and Young, A.B. (1987) Cortical GABAB and GABAA receptors in Alzheimer’s disease: A quantative autoradiographic study. Neurology, 37, 1454–1459.
Cole, J.O. and Branconnier, R. (1978) The therapeutic efficacy of psychopharmacologic agents in senile organic brain syndrome in senile dementia, in Senile Dementia; A Biochemical Approach, (ed K. Nandy), Elsevier, New York, pp. 271–286.
Colino, A. and Halliwell, J.V. (1987) Differential modulation of three separate K-conductances in hippocampal CA1 neurones by serotonin. Nature, 328, 73–77.
Copani, A., Koh, J.Y. and Cotman, C.W. (1991) α-Amyloid increases neuronal susceptibility to injury by glucose deprivation. NeuroReport, 2, 763–765.
Cordi, A.A., Monahan, J.B., and Reisse, J. (1990) A topological model of the NMDA-glycine receptor model. J. Receptor Res., 10, 299–315.
Corsellis, J.A.N. (1962) Mental illness and the ageing brain, in Maudsley Monograph No. 9, Oxford University Press, London, pp. 29–32.
Cowburn, R.F., Hardy, J.A. and Roberts, P.J. (1989) Neurotransmitter deficits in Alzheimer’s disease, in Alzheimer’s Disease Towards an Understanding of the Aetiology and Pathogenesis, (ed. D.C. Davies), Libby, London, pp. 9–32.
Cowburn, R.F., Neil, C.O., Ravid, R. et al. (1992) Adenylyl cylase activity in postmortem human brain: Evidence of altered G protein mediation in Alzheimer’s disease. J. Neurochem., 58, 1409–1419.
Crapper-McLachlan, D.R., Dalton, A.J., Kruck, T.P.A. et al. (1991) Intramuscular desferrioxamine in patients with Alzheimer’s disease. Lancet, 337, 1304–1308.
Cross, A.J., and Slater, P. (1989) High affinity serotonin binding sites in human brain: a comparison of cerebral cortex and basal ganglia. J. Neural. Transm., 76, 211–219.
Cross, A.J., Skan, W.J. and Slater, P. (1986) The association of [3H]-D-aspartate finding and high-affinity glutamate uptakes in the human brain. Neurosci. Lett., 63, 121–124.
Cutler, N.R., Haxby, J.V., Duara, R. et al. (1985) Clinical history, brain metabolism and neuropsychological function in Alzheimer’s disease. Ann. Neurol., 18, 298–309.
Danbolt, N.C. and Storm-Mathisen, J. (1986) Sodium dependent binding of D-aspartate in membranes is largely due to uptake into membrane bound saccules. J. Neurochem., 47, 819–824.
Davies, M.F., Deisz, R.A., Prince, D.A. and Peroutka, S.J. (1987) Two distinct effects of 5-hydroxytryptamine on single cortical neurones. Brain Res., 423, 347–352.
Davies, P. (1991) Therapy for Alzheimer’s disease: choosing a target. Clin. Neuropharmacol., 14, S24–S33.
Davies, K.L., Hollander, E., Davidson, M. et al. (1987) Induction of depression with oxotremorine in Alzheimer’s disease patients. Am. J. Psychiatry, 144, 468–471.
DeFilipe, J. and Jones, E.G. (1988) Cajal on the Cerebral Cortex: An Annotated Translation of the Complete Writings, Oxford University Press, Oxford, pp. 557–621.
Dehlin, O., Hedenrud, B., Janson, P. and Norgaard, J.A. (1985) A double-blind comparison of alaproclate and placebo in the treatment of patients with senile dementia. Acta Psychiatr. Scand., 71, 190–196.
DeKosky, S.T. and Scheff, S.W. (1990) Synapse loss in frontal cortex biopsies in Alzheimer’s disease: correlation with cognitive severity. Ann. Neurol., 27, 457–464.
Dewar, D., Chalmers, D.T., Graham, D.I. and McCullough, J. (1991) Glutamate metabotropic and AMPA binding sites are reduced in Alzheimer’s disease: an autoradiographic study of the hippocampus. Brain Res., 553, 58–64.
Dresse, A. and Scuvee-Moreau, J. (1988) Electrophysiological effects of tianeptine on rat locus coeruleus, raphe dorsalis, and hippocampus activity. Clin. Neuropharmacol., 11, 551–558.
Esiri, M.M., Pearson, R.C.A., Steele, J.E. et al. (1990) A qualitative study of the neurofibrillary tantles and the choline acetyltransferase activity in the cerebral cortex and the amygdala in Alzheimer’s disease. J. Neurol. Neurosurg. Psychiatry, 53, 161–165.
Essman, W.B. (1973) Age dependent effects of 5-hydroxytryptamine upon memory consolidation and cerebral protein synthesis. Pharmacol. Biochem. Behav., 1, 7–14.
Fibiger, H.C. (1991) Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence. Trends Neurosci., 14, 220–223.
Fibiger, H.C., Lepiane, F.G and Phillips, A.G. (1978) Disruption of memory produced by stimulation of the dorsal raphe nucleus: mediation by serotonin. Brain Res., 155, 380–386.
Fletcher, A., Bill, D.J., Brammer, N.T. et al. (1991) WAY 100135: A novel and highly selective 5-HT1A receptor antagonist. Soc. Neurosci., Abs., 17, 92.
Fowler, C.J., O’Neill, C., Garlind, A. and Cowburn, R.F. (1990) Alzheimer’s disease; is there a problem beyond recognition? TIPS, 11, 183–184.
Francis, P.T.and Bowen, D.M. (1989) Tacrine, a drug with therapeutic potential for dementia: post-mortem biochemical evidence. Can. J. Neurol. Sci., 16, 504–510.
Francis, P.T., Bowen, D.M., Neary, D. et al. (1984) Somatostatin-like immunoreactivity in lumbar cerebrospinal fluid from neurohistologically examined demented patients. Neurobiol Aging, 5, 183–186.
Francis, P.T., Palmer, A.M., Sims, N.R. et al. (1985) Neurochemical studies of earlyonset Alzheimer’s disease. Possible influence on treatment. N. Engl. J. Med., 313, 7–11.
Francis, P.T., Bowen, D.M., Lowe, S.L. et al. (1987) Somatostatin content and release measured in cerebral biopsies from demented patients. J. Neurol. Sci., 78, 1–16.
Francis, P.T., Pangalos, M.N., Stephens, P.H. et al. (1993a) Antemortem measurements of neurotransmission: possible implications for pharmacotherapy of Alzheimer’s disease and depression. J. Neurol Neurosurg. Psychiatry, 56, 80–84.
Francis, P.T., Sims, N.R., Procter, A.W. and Bowen, D.M. (1993b) Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer’s disease: investigative and therapeutic perspectives. J. Neurochem., 60, 1589–1604.
Francis, P.T., Pangalos, M.N., Pearson, R.C.A. et al. (1992) 5-HT1A but not 5-HT2 receptors are enriched on neocortical pyramidal neurones destroyed by intrastriatal volkensin. J. Pharmacol Exp. Ther., 261, 1273–1281.
Freeman, S.E. and Dawson, R.M. (1991) Tacrine: A pharmacological review. Prog. Neurol, 36, 257–277.
Geaney, D.P., Soper, N., Shepstone, B.J., Cowen, P.J. (1990) Effect of central cholinergic stimulation on regional cerebral blood flow in Alzheimer’s disease. Lancet, 335, 1484–1487.
Giacobini, E., Linville, D., Messamore, E., Ogane, N. (1991) Toward a third generation of cholinesterase inhibitors, in Cholinergic Basis for Alzheimer’s Therapy, (eds R.E. Becker and E. Giacobini), Birkhauser, Boston, pp. 477–900.
Goodhardt, M.J. (1980) Neurotransmitter uptake and binding in ischaemia and organic dementia, University of London, PhD Thesis.
Greenamyre, J.T. and Young, A.B. (1989) Excitatory amino acids in Alzheimer’s disease. Neurobio. Aging, 10, 593–602.
Greenamyre, J.T., Higgins, D.S. and Young, A.B. (1990) Sodium dependent Dd-aspartate binding is not a measure of presynaptic neuronal uptake sites in an autoradiographic assay. Brain Res., 511, 310–318.
Gustafson, L., Edvinsson, L., Dahlgren, N. et al. (1987) Intravenous physostigmine treatment of Alzheimer’s disease evaluated by psychometric testing, regional cerebral blood flow (rCBF) measurement, and EEG. Psychopharmacology, 93, 31–35.
Gutteridge, J.M., Quinlan, G.J., Clark, G.J. and Halliwell, B. (1985) Aluminium salts accelerate peroxidation of membrane lipids by iron salts. Biochim. Biophys. Acta, 835, 441–447.
Halliwell, J.V. (1986) M-Current in human neocortical neurones. Neurosci. Lett., 67, 1–6.
Harbaugh, R.E. (1987) Intracerebroventricular bethanecol administration in Alzheimer’s disease; preliminary results of a double blind study. J. Neurol. Transm., 24(Suppl.), 271–277.
Hardy, J.A. and Higgins, G.A. (1992) Alzheimer’s disease: the amyloid cascade hypothesis. Science, 256, 184–185.
Harrison, P.J. and Pearson, R.C.A. (1990) In situ hybridisation histochemistry and the study of gene expression in the human brain. Prog. Neurobiol., 34, 271–312.
Hoffman, A., Rocca, W.A., Brayne, C. et al. (1991) The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Int. J. Epidemiol., 20, 736–748.
Hollander, E., Davidson, M., Mohrs, R.C. et al. (1987) RS 86 in the treatment of Alzheimer’s disease: cognitive and biological effects. Biol. Psychiatry, 22, 1067–1078.
Hoyer, D., Schoeffter, P., Palacios, J.M. et al. (1992) A selective, potent and silent 5-HT1A receptor antagonist. Br. J. Pharmacol, (in press).
Hyman, B.T., Van Hoesen, G.W. and Damasio, A.R. (1987) Alzheimer’s disease; glutamate depletion in the hippocampal perforant pathway zone. Ann. Neurol, 22, 37–40.
Iversen, L.L., Bentley, G., Dawson, G. et al. (1991) Heptylphysostigmine— novel acetylcholinesterase inhibitor: biochemical and behavioural pharmacology, in Cholinergic Basis for Alzheimer’s Therapy, (eds R.E. Beckerand E. Giacobini), Birkhansen, Boston, pp. 297–304.
Jansen, K.L.R., Faull, R.L.M., Dragnunow, M. and Synek, B.L. (1990) Alzheimer’s disease; changes in hippocampal N-methyl-D-aspartate, quisqualate, neurotensin, adenosine, benzodiazepine, serotonin and opioid receptors— an autoradiographic study. Neuroscience, 32, 613–627.
Katzman, R. (1976) The prevelance and malignancy of Alzheimer’s disease. Arch. Neurol, 33, 217–218.
Kesslak, J.P., Nalcioglu, O. and Cotman, C.W. (1991) Quantification of magnetic resonance scans for hippocampal and parahippocampal atrophy in Alzheimer’s disease. Neurology, 41, 51–54.
Korey, S.R., Scheinberg, L., Terry, R. and Stein, A. (1961) Studies in presenile dementia. Trans. Am. Neurol Assoc., 86, 99–102.
Lawlor, B.A., Sunderland, T., Mellow, A.M. et al. (1989) Hyperresponsivity to the serotonin agonist m-chlorphenylpiperazine in Alzheimer’s disease: a controlled study. Arch. Gen. Psychiatry, 46, 542–549.
Liau, L.M., Sleight, A.J., Pitha, J. and Peroutka, S.J. (1991) Characterization of a novel and potent 5-hydroxytryptamine1A receptor antagonist. Pharmacol. Biochem. Behav., 38, 555–559.
Lowe, S.L., Francis, P.T., Procter, A.W. et al. (1988) Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer’s disease. Brain, 111, 785–799.
Lowe, S.L., Bowen, D.M., Francis, P.T. and Neary, D. (1990) Ante-mortem cerebral amino acid concentrations indicate selective degeneration of glutamateenriched neurons in Alzheimer’s disease. Neuroscience, 38, 571–577.
McCormick, D.A. and Williamson, A. (1989) Convergence and divergence of neurotransmitter action in human cerebral cortex. Proc. Natl. Acad. Sci, USA, 86, 8098–8102.
McEntee, W.J. and Crook, T.H. (1991) Serotonin, memory, and the aging brain. Psychopharmacology, 103, 143–149.
McLaughlin, M., Ross, B.M., Milligan, G. et al. (1991) Robustness of G proteins in Alzheimer’s disease: an immunoblot study. J. Neurochem., 57, 9–14.
McPherson, G.A. (1985) Analysis of radioligand binding experiments: A collection of computer programs for the IBM PC. J. Pharmacol. Meths., 14, 213–228.
Manallack, D.T., Wong, M.G., O’Shea, R.D. and Beart, P.M. (1990) Topography of the glycine site of the NMDA receptor. Mol. Neuropharmacol., 1, 7–15.
Mantz, J., Godbout, R., Tassin, J.P. et al. (1990) Inhibition of spontaneous and evoked unit activity in the rat medial prefrontal cortex by mesencephalic raphe nuclei. Brain Res., 524, 22–30.
Martin, J.B., Beal, M.F., Mazurek, M. et al. (1988) Some observations on the significance of neurotransmitter changes in Alzheimer’s disease, in Aging and the brain, (ed. R.D. Terry), Raven Press, New York, pp. 129–148.
Mattson, M.P., Cheng, B., Davis, D. et al. (1992) α-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J. Neurosci., 12, 376–389.
Maura, G., Roccatagliatta, E., Ulivi, M. and Raiteri, M. (1988) Serotonin-glutamate interaction in rat cerebellum: Involvement of 5-HT1 and 5-HT2 receptors. Eur. J. Pharmacol., 145, 31–38.
Maura, G., Barzizza, A., Floghera, S. and Raiteri, M. (1991) Release of endogenous aspartate from rat cerebellum slices and synaptosomes: inhibition mediated by a 5-HT2 receptor and by a 5-HT1 receptor of a possibly novel subtype. Naunyn-Schmiederbergs Arch Pharmacol., 343, 229–236.
Millan, M.J., Rivet, J.M., Canton, H. et al. (1991) Benzodioxepiperazine derivatives as novel 5-HT1A antagonists: a pharmacological characterization. Soc. Neurosa. Abs., 17, 92.
Miller, J.D., De Leon, M.J., Ferris, S.H. et al. (1987) Abnormal temporal lobe response in Alzheimer’s disease during congnitive processing as measured by 11C-2-deoxy-D-glucose and PET. J. Cerebr. Blood Flow Metab., 7, 248–251.
Mohr, E., Bruno, G., Foster, N. et al. (1986) GABA-agonist therapy for Alzheimer’s disease. Clin. Neuropharmacol., 9, 257–263.
Mohs, R.C. and Davis, K.L. (1987) The experimental pharmacolocy of Alzheimer’s disease and related dementias, in Psychopharmacology: The Third Generation of Progress, (ed. Meitzer), Raven Press, New York, pp. 921–980.
Mouradian, M.M., Mohr, E., Williams, A.J. and Chase, T.N. (1988) No response to high-dose muscarinic agonist therapy in Alzheimer’s disease. Neurology, 38, 606–608.
Mouradian, M.M., Blin, J., Giuffra, M. et al. (1991) Somatostatin replacement therapy of Alzheimer’s dementia. Ann. Neurol., 30, 610–613.
Murphy, D.L. (1990) Neuropsychiatric disorders and the multiple human brain serotonin receptor subtypes. Neuropsychopharmacology, 3, 457–470.
Near/, D., Snowden, J.S., Mann, D.M. et al. (1986) Alzheimer’s disease: a correlative study. J. Neurol. Neurosurg. Psychiatry, 49, 229–237.
Neary, D., Snowden, J.S., Sheilds, R.A. et al., (1987) Single photon emission tomography using [99m]Tc-HM-PAO in the investigation of dementia. J. Neurol. Neurosurg. Psychiatry, 50, 1101–1109.
Newhouse, P.A., Sunderland, T., Tariot, P.N. et al. (1988) IV nicotine in Alzheimer’s disease, a pilot study. Psychopharmacology, 95, 2–11.
Nyth, A.L. and Gottfries, C.G. (1990) The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. Brit. J. Psychiatry, 157, 894–901.
O’Neill, C., Cowburn, R.F., Weihager, B. et al. (1991) Preservation of 5-hydroxytryptamine1A receptor-G protein interactions in the cerebral cortex of patients with Alzheimer’s disease. Neurosci. Lett., 133, 15–19.
Ogren, S. (1982) Central serotonin neurones and learning in the rat, in Biology of serotonergic transmission, (ed. N.N. Osborne), Wiley, London, pp. 751–763.
Ogren, S. and Johansson, C. (1985) Separation of the associative and nonassociative effects of brain serotonin released by p-chloroamphetamine: dissociable serotonergic involvement in avoidance learning, pain and motor function. Psychopharmacology, 86, 12–26.
Palmer, A.M. (1987) Central monoamine neurones in Alzheimer’s disease, University of London, PhD Thesis, pp. 56-69.
Palmer, A.M., Sims, N.R., Bowen, D.M. et al. (1984) Monoamine metabolite concentrations in lumbar cerebrospinal fluid of patients with histologically verified Alzheimer’s dementia. J. Neurol. Neurosurg. Psychiatry, 47, 481–484.
Palmer, A.M., Francis, P.T., Benton, J.S. et al. (1987a) Presynaptic serotonergic dysfunction in patients with Alzheimer’s disease. J. Neurochem., 48, 8–15.
Palmer, A.M., Francis, P.T., Benton, J.S. et al. (1987b) Catecholaminergic neurones assessed ante-mortem in Alzheimer’s disease. Brain Res., 414, 365–375.
Palmer, A.M., Wilcock, G.K., Esiri, M.M. et al. (1987c) Monoaminergic innervation of the frontal and temporal lobes in Alzheimer’s disease. Brain Res., 401, 231–238.
Palmer, A.M., Stratmann, G.C., Procter, A.W. and Bowen, D.M. (1988) Possible neurotransmitter basis of bahavioural changes in Alzheimer’s disease. Ann. Neurol., 23, 616–620.
Pangalos, M.N. (1992) Biochemical approaches to investigate neocortical pyramidal neurones. University of London, PhD Thesis.
Pangalos, M.N., Francis, P.T., Middlemiss, D.N. et al. (1991) Selective destruction of a sub-population of cortical neurones by suicide transport of volkensin, a lectin from Adenia volkensii, J. Neurosci. Meth., 40, 17–29.
Pazos, A., Probst, A. and Palacios, J.M. (1987) Serotonin receptors in the human brain-III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience, 21, 97–122.
Peinado, J.M. and Mora, F. (1986) Glutamic acid as putative transmitter of the interhemispheric corticocortical connections in the rat. J. Neurochem., 47, 1598–1603.
Penney, J.B., Maragos, W.F., Greenmyre, J.T. et al. (1990) Exictatory amino acid binding sites in the hippocampal region of Alzheimer’s disease and other dementias. J. Neurol. Neurosurg. Psychiatry, 53, 314–320.
Perry, E.K. and Perry, R.H. (1985) A review of neuropathological and neurochemical correlates of Alzheimer’s disease. Danish Med. Bull., 32(Suppl. 1), 27–34.
Perry, E.K., Perry, R.H. and Tomlinson, B.E. (1982) The influence of agonal status on some neurochemical activities of postmortem human brain tissue. Neurosci. Lett., 29, 303–307.
Procter, A.W., Lowe, S.L., Palmer, A.M. et al. (1988a) Topographical distribution of neurochemical changes in Alzheimer’s disease. J. Neurol. Sci., 84, 125–140.
Procter, A.W., Palmer, A.M., Francis, P.T. et al. (1988b) Evidence of glutamatergic denervation and possible abnormal metabolism in Alzheimer’s disease. J. Neurochem., 50, 790–802.
Procter, A.W., Stirling, J.M., Stratmann, G.C. et al. (1989a) Loss of glycinedependent radioligand binding to the N-methyl-D-aspartate-phencyclidine receptor complex in patients with Alzheimer’s disease. Neurosci. Lett., 101, 62–66.
Procter, A.W., Wong, E.H., Stratmann, G.C. et al. (1989b) Reduced glycine stimulation of [3H]MK-801 binding in Alzheimer’s disease. J. Neurochem., 53, 698–704.
Procter, A.W., Stratmann, G.C., Francis, P.T. et al. (1991) Characterization of the glycine modulatory site of the N-methyl-D-aspartate receptor ionophore complex in human brain. J. Neurochem., 56, 299–310.
Procter, A.W., Francis, P.T., Stratmann, G.C. and Bowen, D.M. (1992) Serotonergic pathology is not widespread in Alzheimer patients without prominent behaviour symptoms. Neurochem. Res., 17, 917–922.
Raiteri, M., Maura, G. and Barzizza, A. (1991) Activation of presynaptic 5-HT1-like receptors on glutamatergic terminals inhibits N-methyl-D-aspartate induced cyclic GMP production on rat cerebellar slices. J. Pharmacol. Exp. Therapeut., 257, 1184–1185.
Raiteri, M., Maura, G., Bonanno, G. and Pittaluga, A. (1986) Differential pharmacology and function of two 5-HT1 receptors modulating transmitter release in rat cerebellum. J. Pharmacol. Exp. Ther., 237, 644–648.
Rakonczay, Z. (1988) Cholinesterase and its molecular forms in pathological states. Prog. Neurol., 31, 311–330.
Raskind, M.A., Peskind, E.R., Halter, J.B. and Himerson, D.C. (1984) Norepinephrine and MHPG levels in CSF and plasma in Alzheimer’s disease. Arch. Gen. Psychiatry, 41, 343–346.
Reinikainen, K.J., Paljarvi, L., Huuskonen, M. et al. (1988) A postmortem study of nonadrenergic serotonergic and GABAergic neurones in Alzheimer’s disease. J. Neurol. Sci., 84, 101–116.
Rocca, W.A., Hoffmann, A., Brayne, C. et al. (1991) Frequency and distribution of Alzheimer’s disease in Europe: a collaborative study of 1980-1990 prevalence findings. Ann. Neurol., 30, 381–390.
Rossor, M.N., Emson, P.C., Iversen, L.L. et al. (1982) Neuropeptides and neurotransmitters in cerebral cortex in Alzheimer’s disease, in Alzheimer’s Disease: A Report of Progress. (Aging, Vol. 19), (eds. S. Corkin, K.L. Davis, J.H. Growdon, E. Usdin and R.J. Wurtman), Raven Press, New York, pp. 15–24.
Roth, M. (1955) The natural history of mental disorder in old age. J. Mental Sci., 101, 281–301.
Roth, M., Tomlinson, B.E. and Blessed, G. (1966) Correlation between scores of dementia and counts of’ senile plaques’ in cerebral grey matter of elderly subjects. Nature, 209, 109–111.
Sarter, M. (1991) Taking stock of cognitive enhancers. Trends Pharmacol. Sci., 12, 456–461.
Saunders, J. and Freedman, S.B. (1989) The design of full agonists for the cortical muscarinic receptor. TIPS, 10(Suppl.), 70–75.
Schwartz, B.L., Hashtroudi, S., Herting, R.L. et al. (1991) Glycine prodrug facilitates memory retrieval in humans. Neurology, 41, 1341–1343.
Sheldon, P.W. and Aghajanian, G.K. (1990) Serotonin (5-HT) induces IPSPs in pyramidal layer cells of the rat piriform cortex: Evidence for the involvement of a 5-HT2 activated interneurone. Brain Res., 506, 62–69.
Siesjö, B.K. and Bengtsson, F. (1989) Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischaemia, hypoglycaemia, and spreading depression; a unifying hypothesis. J. Cerebr. Blood Flow Metab., 9, 127–140.
Sijbesma, H., Schipper, J., De Kloet, E.R. et al. (1991) Postsynaptic 5-HT1 receptors and offensive aggression in rat: a combined behavioural and autoradiographic study with eltoprazine. Pharmacol. Biochem. Behav., 38, 447–458.
Sims, N.R. (1990) Altered glucose metabolism in Alzheimer’s disease. Ann. Neurol., 27, 691–692.
Sims, N.R., Bowen, D.M., Allen, S.J. et al. (1983a) Presynaptic cholinergic dysfunction in patients with dementia. J. Neurochem., 40, 503–509.
Sims, N.R., Bowen, D.M., Neary, D. and Davison, A.N. (1983b) Metabolic processes in Alzheimer’s disease: adenine nucleotide content and production of 14CO2 from [U-14C] glucose in vitro in human neocortex. J. Neurochem., 41, 1329–1334.
Sims, N.R., Finegan, J.M., Blass, J.P. et al. (1987) Mitochondrial function in brain tissue in primary degenerative dementia. Brain Res., 436, 30–33.
Small, H.D., Moir, R.D., Fuller, S.J. et al. (1991) A protease activity associated with acetylcholinesterase releases the membrane-bound form of the amyloid protein precursor of Alzheimer’s disease. Biochemistry, 30, 10795–10799.
Smith, C.C.T., Bowen, D.M. and Davison, A.N. (1983) The evoked release of endogenous amino acids from tissue prisms of human neocortex. Brain Res., 269, 103–109.
Smith, C.C.T., Bowen, D.M., Sims, N.R. et al. (1983b) Amino acid release from biopsy samples of temporal neocortex from patients with Alzheimer’s disease. Brain Res., 264, 138–141.
Spillane, J.A., White, P., Goodhardt, M.J. et al. (1977) Selective vulnerability of neurones in organic dementia. Nature, 266, 558–559.
Steele, J.E., Cross, A.J. and Bowen, D.M. (1991) Ligand binding to the N-methyl-D-aspartate receptor in brains from controls and Alzheimer’s disease patients. Br. J. Pharmacol., 104, 242.
Summers, W.K., Majovski, L.V., Marsh, G.M. et al. (1986) Oral tetrahydroaminoacridine in long term treatment of senile dementia Alzheimer type. N. Engl. J. Med., 315, 1241–1245.
Tamminga, C.A., Foster, N.L., Fedio, P. et al. (1987) Alzheimer’s disease: Low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism. Neurology, 37, 161–165.
Tariot, P.N., Sunderland, T., Cohen, R.M. et al. (1988) Multiple-dose arecoline infusions in Alzheimer’s disease. Arch. Gen. Psychiatry, 45, 901–905.
Terry, R.D., Masliah, E., Salmon, D.P. et al. (1991) Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol., 30, 572–580.
Thal, L.J. (1990) THA, A putative drug in the treatment of Alzheimer’s disease? Acta Neurol. Scand., 82, 27–28.
Thompson, T.L., Filley, C.M., Mitchell, W.D. et al. (1990) Lack of efficacy of hydergine in patients with Alzheimer’s diseases. N. Engl. J. Med., 23, 445–448.
Tricklebank, M.D., Hutson, P.H. and Curzon, G.C. (1984) Analgesia induced by brief or more prolonged stress differs in its dependency on naloxone, 5-hydroxytryptamine and previous testing of analgesia. Neuropharmacology, 23, 417–421.
Waeber, C., Dietl, M.M., Hoyer, D. and Palacios, J.M. (1989) 5-HT1-receptors in the vertebrate brain. Regional distribution examined by autoradiography. Naunyn-Schmiedebergs Arch. Pharmacol., 340, 486–494.
Wesnes, K., Jones, R.W. and Kirby, J. (1991) The effects of D-cycloserine, a glycine agonist, in a human model of the cognitive deficits associated with ageing and dementia. Br. J. Clin. Pharmacol., 31, 577–578.
Wetzel, W., Getsova, V.M., Jork, R. and Matthies, H. (1980) Effect of serotonin on Y-maze retention and hippocampal protein synthesis in rats. Pharmacol. Biochem. Behav., 12, 319–322.
White, P., Hiley, C.R., Goodhardt, M.J. et al. (1977) Neocortical cholinergic neurons in elderly people. Lancet, 1, 668–671.
Whitehouse, P.J., Price, D.L., Strubble, R.G. et al. (1982) Alzheimer’s disease and senile dementia: loss of neurones in basal forebrain. Science, 215, 1237–1239.
Whitehouse, P.J., Martion, A.M., Marcus, K.A. and Zweig, R.M. (1988) Reductions in acetylcholine and nicotine binding in several degenerative diseases. Arch. Neurol., 45, 722–724.
Wilkins, R.H. and Brody, I.A. (1969) Alzheimer’s Disease. Arch. Neurol., 21, 109–110.
Wilson, R.S. and Martin, E.M. (1988) New intrathecal drugs in Alzheimer’s disease and psychometric testing. Annal. New York Acad. Sci., 531, 180–186.
Yates, C.M., Butterworth, J., Tennant, M.C. and Gordon, A. (1990) Enzyme activities in relation to pH and lactate in postmortem brain in Alzheimer-type and other dementias. J. Neurochem., 55, 1624–1630.
Zilles, K., Zur Nieden, K., Schleicher, A. and Traber, J. (1990) A new method for quenching correction leads to revisions of data in receptor autoradiography. Histochemistry, 94, 569–578.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media Dordrecht
About this chapter
Cite this chapter
Francis, P.T., Bowen, D.M. (1994). Neuronal pathology in relation to molecular biology and treatment of Alzheimer’s disease. In: Owen, F., Itzhaki, R. (eds) Molecular and Cell Biology of Neuropsychiatric Diseases. Molecular and Cell Biology of Human Diseases Series. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-0709-9_2
Download citation
DOI: https://doi.org/10.1007/978-94-011-0709-9_2
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-010-4305-2
Online ISBN: 978-94-011-0709-9
eBook Packages: Springer Book Archive